hemotune AG appoints Harald Casebourne Stock as President of the Board of Directors

hemotune AG a developer of blood purification technology poised to enter the clinical stage and enable breakthrough interventions for the most urgent medical needs, today announced the appointment of Harald Casebourne Stock as President of the company’s Board of Directors. Perry van Rijsingen, who has chaired the Board since 2019 has stepped down, staying closely involved as an advisor.

Harald Casebourne Stock, PhD is Executive Partner at Yarvie, a creator and shaper of enterprises working towards a world in which everyone can thrive. His executive and board track record spans diagnostics, devices and medical equipment at Roche, J&J and Arjo; therapeutics and cell therapies at Grünenthal, Ovascience and Eptiva Therapeutics; and digital health at Cognifisense. As CEO he led companies of over $1B revenue, with global footprint, and over 5,000 employees – as a co-founder, he has started companies as one of the first team members, and shaped scaling past regulatory approval to commercial stage. To date, Harald has been actively involved in over 50 new product introductions, five public listings, financings totaling over $1B, and multiple strategic partnering transactions. Besides this new role at hemotune AG, he currently is an active co-founder at Cognifisense (as NED), Eptiva Therapeutics and Domus Diagnostics (both as Executive Chair), in addition to holding an NED role at Consilient Health.

Harald Casebourne Stock: New President of the Board at hemotune AG

Lukas Langenegger, founding CEO of hemotune AG says: “On behalf of the entire hemotune team, our shareholders, and our Board, I am delighted to welcome Harald. We are at an important juncture in hemotune’s journey, now as we prepare to treat our first patients and expand the applications of our groundbreaking technology. Harald’s profile is a great addition to our team at this point of the company’s development. I would also like to thank Perry very much for five years of successful, collaborative thought partnership, which has been a pleasure both professionally and personally.”

Perry van Rijsingen, outgoing President of the Board at hemotune AG adds: “It’s been a true pleasure supporting Lukas and the team over the last years. The company has made significant progress, and with my successor as chair, the management team, the Board and hemotune’s investor base, we are set up for success in the next phase of hemotune’s development.”

“I am excited to join hemotune AG and becoming part of shaping its future. The company’s technology has significant potential to benefit patients globally. Lukas, Carlos and the team have advanced the company in an impressive way over the last six years and have been able to attract funding from leading European investors. I’d like to thank our shareholders and the Board for their trust and look very much forward to working together.” states Harald Casebourne Stock.

Hemotune AG appoints Harald Casebourne Stock.pdf

PDF herunterladen • 173KB